Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for heart patients with brain bleed history: catheter ablation vs. standard care

NCT ID NCT07316270

Disease control Sponsor: Beijing Anzhen Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This study compares catheter ablation (a procedure to fix irregular heartbeats) with standard medical care in 646 adults who have both atrial fibrillation and a recent brain bleed. The goal is to see if ablation reduces the risk of death, stroke, or blood clots. Participants must be between 14 days and 12 months after their brain bleed and have a high stroke risk score.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 646 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years 2. Between 14 Days and 12 Months After Spontaneous Intracranial Hemorrhage (intraparenchymal or intraventricular hemorrhage, and subdural hematoma) 3. Able to Access Intracranial Hemorrhage Imaging Data 4. ECG indicating the presence of atrial fibrillation 5. CHA₂DS₂-VA Score ≥ 2 6. Willing to undergo randomization and able to complete follow-up as required Exclusion Criteria: 1. Atrial fibrillation secondary to clearly reversible causes (e.g., hyperthyroidism, hypokalemia, etc.) 2. Fully dependent (modified Rankin Scale \[mRS\] score \> 4) 3. Uncontrolled hypertension (systolic blood pressure \> 160 mmHg) 4. Presence of uncontrolled active bleeding 5. Presence of active infection requiring antibiotic treatment 6. End-stage renal failure or receiving dialysis treatment 7. Presence of liver failure 8. Untreated coronary artery disease with indication for revascularization 9. Presence of intracardiac masses, thrombi, etc., as evaluated by transthoracic echocardiography or transesophageal echocardiography 10. Expected life expectancy \< 1 year (e.g., advanced malignant tumors, etc.) 11. Pregnant, lactating, or women planning to become pregnant 12. Presence of psychological or psychiatric disorders that prevent understanding or cooperation with the study 13. Other conditions deemed unsuitable for participation in the study by the investigators

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Af - atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation intracerebral hemorrhage Intracranial Hemorrhages

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Af - atrial fibrillation Ich - intracerebral hemorrhage Intracranial hemorrhage, spontaneous

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Anzhen Hospital, Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, 100029, China

  • The First Affiliated Hospital of Anhui Medical University

    NOT_YET_RECRUITING

    Hefei, Anhui, 230022, China

  • The First Affiliated Hospital of Harbin Medical University

    NOT_YET_RECRUITING

    Harbin, Heilongjiang, 150001, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    NOT_YET_RECRUITING

    Xi'an, Shaanxi, China

  • The First Hospital of Jilin University

    NOT_YET_RECRUITING

    Changchun, Jilin, China

  • The Second Affiliated Hospital of Harbin Medical University

    NOT_YET_RECRUITING

    Harbin, Heilongjiang, China

  • Xiamen Cadiovascular Hospital

    RECRUITING

    Xiamen, Fujian, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.